Cancer

Article	Citations
Issue Information	363
Sharp rise in esophageal cancer and Barrett esophagus seen in middle‐aged people	237
Issue Information	192
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	172
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	147
Updated American Cancer Society lung cancer screening guidelines	138
Issue Information	123
	112
Cutaneous β‐HPV may predict cutaneous squamous cell carcinoma	111
Issue Information	108
New standard of care for multiple myeloma?	105
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	104
	88
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	78
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	76
A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer	73
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non‐Indigenous men in a universal health care system	72
The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries	59
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases	59
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	59
Association between visceral adiposity index and cancer risk in the UK Biobank cohort	59
Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer	56
	54
Accelerated approval of multiple myeloma therapies	53
New test for detecting cervical adenocarcinoma	53

Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies	52
	52
	51
Let's ask the patient: Self‐reported quality‐of‐life measures help to predict kidney cancer mortality	50
Ovarian juvenile granulosa cell tumor: A report from the International Ovarian and Testicular Stromal Tumor and International Pleuropulmonary Blastoma/DICER1 Registries	50
Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana	49
Active Living After Cancer: Adaptation and evaluation of a community‐based physical activity program for minority and medically underserved breast cancer survivors	49
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	48
Evaluation of headache in patients with cancer	47
Impact of TAILORx on chemotherapy prescribing and 21‐gene recurrence score–guided treatment costs in a population‐based cohort of patients with breast cancer	46
Impact of African ancestry on the relationship between body mass index and survival in an early‐stage breast cancer trial (ECOG‐ACRIN E5103)	45
Reply to “Empathic communication: The premise of inclusive care for historically excluded populations”	45
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data (SOGI) to ensure	45
What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high‐risk of breast cancer? A systematic review and network	45
The economics of advanced and unresectable hepatocellular carcinoma	45
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing	44
Potential of circulating tumor DNA to refine immunotherapy	44
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?	44
What enhanced recovery means for patients with cancer undergoing surgery	44
Top advances of the year: Cervical cancer	43
Epistemic equity in oncology: Opportunities to leverage patient‐centric implementation in clinical trial design	43
Dietary supplement use among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study	41
Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study	41
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	41
Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery	40
Aspirin but not statins is inversely related to gastric cancer with a duration–risk effect: Results from the Stomach Cancer Pooling Project Consortium	40
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1	39
Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers	39
	39
Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials	38
Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data	38
Association of high‐dose radiotherapy with improved survival in patients with newly diagnosed low‐grade gliomas	38
Family characteristics and childcare patterns associated with early social functioning in cancer‐bereaved parents	38
What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?	38
Occurrence of breast‐cancer–related lymphedema after reverse lymphatic mapping and selective axillary dissection versus standard surgical treatment of axilla: A two‐arm randomized clinical trial	37
International perspectives on the development, application, and evaluation of a multicancer early detection strategy	37
Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study	37
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer	37
Top advances of the year: Neoadjuvant immunotherapy in melanoma	36
“Cancer Statistics, 2025” provides data on cancer occurrence and outcomes	36
Characteristics of clinical trials of new oncology drugs approved in China	35
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	35
Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality	35
The critical need to implement and utilize patient‐reported measures of function in cancer care delivery	34
Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy	34
A guide to large data sets for population‐based cancer research: Strengths, limitations, and pitfalls	34
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	34
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	34
Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion	34
Long‐term follow‐up of a phase 2 study of all‐trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia	33

Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	33
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	33
Cancer‐related impairments and functional limitations among long‐term cancer survivors: Gaps and opportunities for clinical practice	32
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation	32
Effect of an mHealth intervention on physical activity outcomes among young adult cancer survivors: The IMPACT randomized controlled trial	32
Recent histone deacetylase inhibitors in cancer therapy	32
Breast cancer survival in India across 11 geographic areas under the National Cancer Registry Programme	32
	31
Safety, efficacy, and pharmacokinetics of SH‐1028 in EGFR T790M‐positive advanced non–small cell lung cancer patients: A dose‐escalation phase 1 study	31
Smoking cessation services and shared decision‐making practices among lung cancer screening facilities: A cross‐sectional study	31
Issue Information	31
Issue Information	31
Standard of care for children with newly diagnosed B‐cell ALL	31
Keep moving to prevent cancer	31
Issue Information	31
Issue Information	31
Targeting ROS1 rearrangements in non–small cell lung cancer: Current insights and future directions	31
Making a case for del(1p) as a high‐risk abnormality in multiple myeloma	30
Comparison of long‐term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia‐positive acute lymphoblastic leukemia: A multicente	30
Fecal microbiota transplantation for immunotherapy‐resistant urological tumors: Is it time? An update of the recent literature	30
Cardiac remodeling after anthracycline and radiotherapy exposure in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study	30
Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial	30
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma	29
	29
Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer	29
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies	29
Association of mental health treatment receipt with cancer screening among US adults with a history of anxiety or depression	29
Helping patients with cancer to understand secondary findings on genetic tests	29
	29
Associations between geography, decision‐making style, and interest in cancer clinical trial participation	28
Peripheral blood parameter abnormalities precede therapy‐related myeloid neoplasms after autologous transplantation for lymphoma	28
Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: A Dutch Childhood Cancer Survivor LATER 2 study	28
Association between treatment‐emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study	28
Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations	28
Acute hospitalizations after proton therapy versus intensity‐modulated radiotherapy for locally advanced non–small cell lung cancer in the durvalumab era	28
Cervical cancer elimination in Indian context: Moving from barriers to facilitators	27
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT–confirmed complete response	27
Lost in the shadow of giants: The neglected treatment modalities in oncologic trials	27
Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: “Repeat and replicate”	26
Impact of the COVID‐19 pandemic on pediatric oncology providers globally: A mixed‐methods study	26
The American Cancer Society National Lung Cancer Roundtable strategic plan: Introduction	26
Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life	26
Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia	26
Continuity and coordination of care for childhood cancer survivors with multiple chronic conditions: Results from the Childhood Cancer Survivor Study	26
Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer	26
A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers	26
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis	26
Beyond the PSA: The hidden costs of screening in prostate cancer	26
The use of national datasets to evaluate outcomes for invasive lobular carcinoma	26
Anti‐Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It’s complicated	26
Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer	25
Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial	25
A call to action to advance patient‐focused and decentralized clinical trials	25
Associations between experiences of discrimination and quality of life in Black breast cancer survivors	25
From childhood cancer to metabolic syndrome	25
	25
Utilization and perceptions of chaplaincy among hospitalized adults of Dharmic religions with cancer	25
Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia	25
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease	25
The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative	24
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 tri	24
Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma	24
A randomized prospective trial of an ostomy telehealth intervention for cancer survivors	24
The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance	23
A Coala‐T‐Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment	23
Liver transplantation for hepatic epithelioid hemangioendothelioma	23
Impact of acupuncture and integrative therapies on chemotherapy‐induced peripheral neuropathy: A multicentered, randomized controlled trial	23
Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma	23
Sex disparities in the incidence of 21 cancer types: Quantification of the contribution of risk factors	23
Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS‐5	23
Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?	23
Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer	23
Young adult males have worse survival than females that is largely independent of treatment received for many types of central nervous system tumors: A National Cancer Database analysis	23
Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer	23
Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma	22
Lung cancer screening associated with earlier diagnosis and improved survival	22
Reasons for refusal of the human papillomavirus vaccine among young cancer survivors	22
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial	22
Palliative care training can help patients with advanced cancer at the end of life	22
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?	22

Preclinical data suggest role of dopamine in preventing select skin cancers	22
Increased health‐related quality of life impairments of male and female survivors of childhood cancer: DCCSS LATER 2 psycho‐oncology study	22
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding	22
Is repeat breast conservation possible for small ipsilateral breast cancer recurrence?	22
First person profile: Robert C. Bast Jr MD	22
Breast health equity along the cancer care continuum: A collaborative grant initiative	21
Primary osteosarcoma of the ribs: A report from the Cooperative Osteosarcoma Study Group	21
An editorial on a comparison of care quality metrics between Black and White men with advanced prostate cancer in the IRONMAN registry	21
Targeted genotyping for recurring variants in cancer susceptibility genes in non‐Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years	21
Top advances of the year in colorectal cancer	21
Endoscopic balloon cryoablation plus transurethral resection for bladder cancer: A phase 2, multicenter, randomized, controlled trial	21
Implementation and evaluation of a remote geriatric assessment and intervention program in Brazil	21
Multidimensional structural racism and estimated cancer risk from traffic‐related air pollution	21
Cancer treatment in the time of COVID‐19 pandemics: A new concern	21
Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IM	21
Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP‐WT‐2001 protocol in the UK‐CCLG and GPOH studies (2001–2020)	21
Geographic diffusion of digital mammography in the United States	21
Hepatocellular carcinoma, vascular endothelial growth factor receptors‐targeting agents, and hypertension: A much more complicated relationship than expected	21
Oncologists’ role in end‐of‐life chemotherapy and patient‐centered care	21
Association of mental health diagnosis with race and all‐cause mortality after a cancer diagnosis: Large‐scale analysis of electronic health record data	20
Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high‐risk population: A cross‐sectional study	20
Reply to “Another look at floor and ceiling effects in the EORTC QLQ‐C30 Physical Functioning subscale and possible solutions”	20
Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients	20
The impact of the COVID‐19 pandemic on African American cancer survivors	20
Association between exposures to radon and γ‐ray radiation and histologic type of lung cancer in Eldorado uranium mining and milling workers from Canada	20
Effects by educational attainment of a mammography screening patient decision aid for women aged 75 years and older	20
Issue Information	20
Association between the amount of artificial hydration and quality of dying among terminally ill patients with cancer: The East Asian Collaborative Cross‐Cultural Study to Elucidate the Dying Process	20
Gaps in care highlight the need to expand access to clinical cancer trials	19
Comparison of survival outcomes for patients with Stage III vs de novo Stage IV breast cancer	19
A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India	19
Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters	19
AACR 2024 presents advancements in pancreatic and gastric cancers	19
CD123 expression linked to high‐risk disease in children with acute myeloid leukemia	19
Nomogram predicts survival and surgical benefits for patients with breast cancer with initial bone metastasis: A population‐based study	19
Disparities in phase 1 cancer clinical trial enrollment	19
Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study	19
	19
Issue Information	19
First person profile: Fadlo R. Khuri, MD	19
Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021	19
The relationship of mental health symptoms to chemotherapy toxicity risk in older adults with cancer: Results from the geriatric assessment–driven intervention study	19
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry	19
Cyclin‐dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple‐negative breast cancer by affecting the immune microenvironment	19
Erratum to “Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children’s Oncology Group”	19
Cannabis use among adults undergoing cancer treatment	18
Associations of serum trimethylamine N‐oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort	18
Alarming recent rises in early‐onset colorectal cancer	18
Defining disease modification in myelofibrosis in the era of targeted therapy	18
	18
Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study	18
Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study	18
Top advances of the year: Targeted therapy for lung cancer	18
A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas	18
CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study	18
Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities	18
Health‐related quality of life outcomes after neoadjuvant chemoradiotherapy for rectal cancer in NRG Oncology/NSABP R‐04	18
Phase 1 trial of intraperitoneal paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology	18
Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial	18
Disease characteristics and mortality among Asian women with breast cancer	18
	18
	18
First person profile: Julie Brahmer, MD	17
Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study	17
Historical redlining and survival among children, adolescents, and young adults with cancer diagnosed between 2000–2019 in Seattle and Tacoma, Washington	17
Systemic therapies at the end of life vary by patient and practice	17
Caring for caregivers in early‐phase clinical oncology trials	17
Issue Information	17
Insulin resistance during androgen deprivation therapy in men with prostate cancer	17
Top advances of the year: Cervical cancer	17
Issue Information	17
Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a survey	17
Erratum to “Use of a clinical trial screening tool to enhance accrual”	17
Cancer survivors have an increased risk of cardiovascular disease	17
Issue Information	17
Chronic conditions, cancer disparities, and the unique needs of Black women with ovarian cancer	17
Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer	17
The cost burden of metastatic prostate cancer in the US populations covered by employer‐sponsored health insurance	17
Issue Information	17
Issue Information	17
	17
Issue Information	17
Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB‐positive acute lymphoblastic leukemia patients: A retrospective multicenter study	16
Reply to “How should decision aids be developed, and which patient outcomes should be assessed?”	16
Comparing clinical and nonclinical cancer patient navigators: A national study in the United States	16
Cumulative exposure to impaired fasting glucose and gastrointestinal cancer risk: A nationwide cohort study	16
Potential new standard of care for the first‐line treatment of metastatic colorectal cancer	16
Switching the scope from “how to identify cancer survivors” to “who is participating in cancer survivorship research”: A proposal for a new focus	16
Locus‐of‐care disparities in end‐of‐life care intensity among adolescents and young adults with cancer: A population‐based study using the IMPACT cohort	16
Reply to Benefit‐harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10	16
Reply to “Vitamin D and breast cancer: Stop torturing the data!”	16
Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, and Germany using r	16
Generalizing approaches to surveillance for complex social outcomes in broad‐range patient populations—The cost in terms of lost information and subgroup utility	16
Universal social needs assessment in gynecologic oncology: An important step toward more informed and targeted care in the public safety net	16
Air pollution was high centuries before industrial revolutions and may have been responsible for cancer rates in medieval Britain	16